Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) was down 6.9% during mid-day trading on Friday . The stock traded as low as $15.07 and last traded at $15.54. Approximately 33,377 shares changed hands during trading, a decline of 52% from the average daily volume of 69,255 shares. The stock had previously closed at $16.69.
Rapport Therapeutics Stock Performance
The business's 50-day moving average is $20.85.
Institutional Trading of Rapport Therapeutics
Large investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. bought a new stake in Rapport Therapeutics during the third quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new stake in Rapport Therapeutics during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. bought a new stake in Rapport Therapeutics during the third quarter valued at approximately $83,000. SG Americas Securities LLC bought a new position in shares of Rapport Therapeutics in the third quarter worth approximately $101,000. Finally, Sandia Investment Management LP bought a new position in shares of Rapport Therapeutics in the second quarter worth approximately $116,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Recommended Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
